AIMZ Investment Advisors LLC Makes New $3.53 Million Investment in Genmab A/S (NASDAQ:GMAB)

AIMZ Investment Advisors LLC bought a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 168,905 shares of the company's stock, valued at approximately $3,525,000. Genmab A/S makes up approximately 1.2% of AIMZ Investment Advisors LLC's holdings, making the stock its 26th biggest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in shares of Genmab A/S by 4.0% during the fourth quarter. Bank of New York Mellon Corp now owns 71,623 shares of the company's stock valued at $1,495,000 after acquiring an additional 2,749 shares during the last quarter. Y Intercept Hong Kong Ltd raised its position in Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company's stock worth $1,538,000 after purchasing an additional 58,048 shares during the last quarter. Cromwell Holdings LLC lifted its holdings in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares during the period. ABC Arbitrage SA bought a new stake in shares of Genmab A/S in the 4th quarter valued at about $3,692,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Genmab A/S by 229.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after buying an additional 34,652 shares during the period. Institutional investors own 7.07% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $42.17.

Genmab A/S Trading Up 1.4 %

GMAB stock traded up $0.33 during midday trading on Tuesday, reaching $23.29. 630,295 shares of the company's stock traded hands, compared to its average volume of 856,197. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The stock has a market cap of $15.41 billion, a P/E ratio of 13.42, a PEG ratio of 2.65 and a beta of 0.96. The stock's 50-day moving average is $21.03 and its 200 day moving average is $22.72.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.